Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Depreciation & Amortization (CF) (2016 - 2025)

Ptc Therapeutics (PTCT) has 14 years of Depreciation & Amortization (CF) data on record, last reported at $12.9 million in Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 90.75% year-over-year to $12.9 million; the TTM value through Dec 2025 reached $38.8 million, down 48.7%, while the annual FY2025 figure was $38.8 million, 48.7% down from the prior year.
  • Depreciation & Amortization (CF) reached $12.9 million in Q4 2025 per PTCT's latest filing, up from $11.1 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $80.7 million in Q4 2023 and bottomed at $6.5 million in Q3 2024.
  • Average Depreciation & Amortization (CF) over 5 years is $27.2 million, with a median of $17.8 million recorded in 2021.
  • Peak YoY movement for Depreciation & Amortization (CF): surged 107.65% in 2023, then plummeted 91.62% in 2024.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $18.8 million in 2021, then soared by 106.61% to $38.9 million in 2022, then skyrocketed by 107.65% to $80.7 million in 2023, then tumbled by 91.62% to $6.8 million in 2024, then skyrocketed by 90.75% to $12.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $12.9 million in Q4 2025, $11.1 million in Q3 2025, and $7.6 million in Q2 2025.